Ivermet

Quick links to important sections

Ivermet

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivermet

Quick Facts

Property Description
Active ingredient Ivermectin (INN)
Form Tablet (oral), Lotion, or Cream (topical)
Pharmacological class Anthelmintic / Endectocide
General purpose Combating parasitic infestations
Origin Semi-synthetic macrocyclic lactone

What Type of Medicine is Ivermet (Ivermectin)?

Ivermet is a medicinal product containing the active ingredient Ivermectin, which is widely recognized as an essential anthelmintic and a broad-spectrum antiparasitic drug. This core classification defines its purpose: to eliminate or control infestations caused by susceptible parasitic worms and external arthropods. Ivermectin is a semi-synthetic macrocyclic lactone, a chemical derivative originally isolated from the fermentation products of the soil bacterium Streptomyces avermitilis.

The drug is specifically categorized as an endectocide, which is a differentiating feature. This designation means the medicine has demonstrated activity against both endoparasites (internal worms) and certain ectoparasites (external organisms like mites and lice), offering a versatile application against various parasitic diseases.


Identity and Form Differentiation

Ivermectin is a purified mixture of two closely related components (known as B1a and B1b) and is known for its high potency. This unique composition contributes to its efficacy at low therapeutic concentrations. For human use, Ivermectin is commonly available as an oral tablet for systemic absorption, as well as distinct topical formulations such as lotions or creams for localized applications to the skin.


Pharmacological Class and General Principle

Ivermectin functions by causing selective neuromuscular paralysis in the targeted parasitic organism without significantly affecting the human host. It achieves this by binding with high affinity to specific ion channels on the parasite’s nerve and muscle cells, which rapidly disrupts nerve signaling. This high specificity results in the rapid immobility and death of the parasite, defining the drug's effectiveness for parasitic control.

What side effects are possible with Ivermet?

The safety profile of Ivermet (Ivermectin) is strictly defined in regulatory documents based on the route of administration and the context of treatment. Adverse reactions are classified by frequency and System Organ Class (SOC) to provide a clear overview.


Adverse Reaction Scope

Component Description (Regulatory Summary)
Key Adverse Reaction Categories Systemic adverse events (oral form) and localized skin reactions (topical form).
Frequency Classification Common reactions for the oral form include pruritus (itching), dizziness, headache, somnolence (drowsiness), nausea, diarrhea, and transient increases in liver enzyme levels.
System-Organ Classes Involved Nervous System Disorders (dizziness, headache); Gastrointestinal Disorders (nausea, diarrhea, abdominal pain); Skin and Subcutaneous Tissue Disorders (pruritus, rash); General Disorders (fever, asthenia).
Serious Adverse Reactions The Mazzotti reaction is a serious, systemic inflammatory response tied to the rapid death of parasites (e.g., in onchocerciasis), which may involve fever, hypotension, and arthralgia. Rare serious neurological events, including seizures and encephalopathy, have been reported.

Population-Specific Safety Considerations

Official labeling requires caution for specific patient groups. Safety is not established for pregnant or breastfeeding women, and use is only permitted when the potential benefit is judged to outweigh the potential risk. Caution is necessary for individuals with impaired liver function (hepatic impairment) because the medicine is primarily metabolized in the liver, which could lead to increased concentrations. The medicine is contraindicated in patients with known hypersensitivity to Ivermectin or any component of the formulation.

Most adverse reactions observed with the oral tablet are described as transient (short-lived), and the severity of certain parasitic-death-related reactions is noted to be correlated with the pre-treatment parasitic load.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Ivermet (Ivermectin) overdose is based strictly on reports documented in official government regulatory sources.

Overdose may occur with the ingestion of inappropriately high doses, including the use of unauthorized or veterinary formulations. Since no specific antidote is available for Ivermectin toxicity, all management is primarily symptomatic and supportive.


Documented Manifestations of Overdose

The clinical effects of overdose can range from moderate symptoms to severe, life-threatening outcomes:

  • Gastrointestinal Symptoms: Nausea, Vomiting, Diarrhea, and Abdominal pain.
  • Cardiovascular Effects: Hypotension (low blood pressure) and Tachycardia (rapid heart rate).
  • Neurological Effects: Drowsiness, Confusion, Ataxia (loss of coordination), Tremors, Visual hallucinations, and Loss of consciousness.

Severe Outcomes and Required Actions

The potential for Severe CNS Depression, Seizures, and Coma is documented in regulatory sources following significant ingestion. Due to this risk:

  • Immediate Medical Attention is Required: If an overdose is suspected or any symptoms of toxicity are present, seek immediate medical treatment.
  • Call Emergency Services: If the individual has collapsed, has a seizure, or is difficult to awaken, call emergency services immediately (e.g., 911).

Therapeutic Uses of Ivermet

What Ivermet Treats: Main Uses and Benefits

This medication is primarily used to address the significant discomfort and functional strain caused by internal and external parasitic infections in humans. It is commonly used across conditions presenting with systemic or localized discomfort and is relevant in situations involving certain distressing symptoms.

It is applied across domains where additional symptomatic support is needed, helping address symptom clusters that may become intense or disruptive, including severe, chronic itching, widespread rashes, and gastrointestinal distress. In clinical settings marked by heightened patient distress, this medicine assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Symptoms related to Physical Discomfort

This medication is relevant in contexts involving heightened systemic burden where functional stability becomes affected. It may be part of symptomatic management used to address conditions associated with acute or disruptive episodes. As a patient might summarize the benefit: “It is commonly used to help ease the overall symptom burden.”

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ivermet?

Eligibility for Ivermet (Ivermectin) is strictly defined by regulatory guidelines and is based on weight, age, and existing medical conditions. The oral tablet is contraindicated for patients with a known hypersensitivity to Ivermectin or a history of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), following previous use.


Age and Weight Requirements

Formulation Minimum Eligibility Regulatory Status
Oral Tablet Weighing 15 kilograms or more Safety and efficacy not established below this weight
Topical 6 months of age or older Approved for use from this age

Conditional and Restricted Use

Certain populations must use Ivermet under specific restrictions or with caution.

  • Pregnancy and Lactation: Use is generally not recommended during pregnancy as safety has not been established. Caution is advised during breastfeeding due to drug excretion into human milk.
  • Comorbid Conditions: Caution is required for patients with known hepatic impairment (liver problems).
  • Special Populations: Patients who are immunocompromised or have co-infection with Loa loa require careful medical assessment and follow-up, as their use is subject to specific conditional restrictions outlined in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific medicines and substances that may alter the exposure or effects of Ivermet (Ivermectin).


Interaction Scope and Classification

Interaction Type Interacting Medicines/Classes Interaction-Related Constraint
Pharmacodynamic Warfarin (Anticoagulants) Post-marketing reports indicate a potential increase in the anticoagulant effect, requiring monitoring of coagulation tests, such as the INR.
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., specific antifungals like ketoconazole, posaconazole, itraconazole) These medicines may increase Ivermet plasma concentrations, as Ivermet is primarily metabolized by the CYP3A4 enzyme. Increased concentration may necessitate caution.
Food/PK High-fat meal Administration with a high-fat meal has been documented to increase the bioavailability of Ivermet by approximately 2.5-fold.

Regulatory Summary

Regulatory documents establish that the co-administration of Ivermet with strong CYP3A4 inhibitors or a high-fat meal results in a clinically significant increase in drug exposure. This pharmacokinetic constraint dictates the need for consistent administration in a fasted state to maintain predictable systemic levels. Furthermore, the pharmacodynamic interaction with warfarin highlights the need for heightened monitoring of coagulation parameters due to the potential for an enhanced effect.

Mechanism of Action

The effect of Ivermet is driven by a selective pharmacological mechanism that targets the nervous system of the parasite while exhibiting differential activity in the human host. The core action involves manipulating critical ion flow in the parasite's nerve and muscle cells.

The mechanism begins at the molecular level with Glutamate-Gated Chloride Ion Channels (GluCls), receptors found uniquely on the nerve cells of susceptible parasites. Ivermectin acts as a positive allosteric modulator, binding to these channels and locking them in an open state, establishing the drug's selectivity for the parasitic organism.

The continuous channel activation leads to a massive, uncontrolled influx of negatively charged chloride ions (Cl^-) into the cell. This severe electrical imbalance causes sustained cellular hyperpolarization, which prevents the nerve and muscle cells from generating action potentials. The physiological consequence is immediate and irreversible flaccid paralysis of the parasite's motor system, resulting in the functional cessation of the organism's motor system.

The mechanism is largely confined to the parasite due to dual-level selectivity, involving both the absence of the primary target (GluCls) in mammals and the function of the host's P-glycoprotein (P-gp) efflux pump at the blood-brain barrier. This actively restricts the drug's entry into the central nervous system, which limits its interaction with host central nervous system pathways.

Dosage and Administration Information

How to Use Ivermectin: Administration Guidelines

Ivermectin tablets must be used strictly according to the standard procedures. This section summarizes the standard instructions for the oral tablet formulation.


Administration Requirements

Requirement Instruction
Route of Administration Oral route only for the tablet formulation.
Timing Relative to Meals Must be taken on an empty stomach. No food should be consumed two hours before or two hours after administration.
Preparation Swallow the tablet(s) whole with water. For children under six years of age (and 15 kg), tablets should be crushed before swallowing.

Official Dosing and Schedule

Dosage is determined by body weight (mu g/ kg) and the specific infection, which dictates the number of 3 mg tablets required.

  • Standard Dosing: The typical dose for strongyloidiasis is a single oral dose of approximately 200 mcg/kg. For onchocerciasis, the standard dose is approximately 150 mcg/kg.
  • Frequency: The regimen is typically a single oral dose for initial treatment. Re-treatment is not generally scheduled but may be required if tests confirm persistence of the infection (strongyloidiasis) or recurrence (onchocerciasis), which can occur in cycles of 3 to 12 months.

Procedural Summary

Standard use requires calculating the precise number of tablets based on the patient's current weight. The calculated dose must be taken with water while fasting, thereby structuring the use protocol around the single-dose, empty-stomach administration condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ivermet

Evidence for use in Intestinal Parasite Infections

Studies conducted during periods of increased symptom activity from parasitic infection have included randomized controlled trials (RCTs) comparing Ivermet with other medications. Research examined outcomes related to parasitological cure, measured by laboratory tests confirming the elimination of parasite larvae in stool samples. These studies primarily included adults and children in areas where the infection is common or for chronic cases.

Findings describe patterns related to parasitic clearance measurements over defined time intervals. Evidence for this indication contributes to the broader evidence landscape, but the exact time needed to confirm complete and lasting parasitic clearance across all patients remains an area of scientific discussion. Limited information is available for long-term outcomes in specific patient groups, such as those with compromised immune systems.


Evidence for use in Tissue-Dwelling Parasite Infections

For Onchocerciasis (river blindness), research has explored the drug’s role through large-scale community trials and long-term observational studies. These studies monitored the microfilarial load reduction, a measurement of the larval parasite count in the skin and eye, and examined how these counts changed over extended time periods.

Research monitored patterns related to changes in these parasite counts in the populations studied. The studies primarily focused on measuring changes in the larval stage; the research explored the impact on the adult parasite, with findings indicating that this effect is often limited in the context of the trials. Given the measured patterns of change in the larval stage, the research designs often involved long-term monitoring and predefined re-treatment schedules.


Evidence for use in External Parasite Infestations

Studies for external infestations like scabies included RCTs evaluating both the oral tablet and the topical cream forms. Research examined outcomes related to complete parasitic clearance and patient-reported outcomes describing perceived discomfort, such as the change in the severity of itching (pruritus).

Findings describe patterns observed in the studies where Ivermet was observed to have outcomes related to the measured clearance of the external parasite. Evidence quality varies across studies, with some having small sample sizes or limited follow-up durations. Comparative evidence against all standard treatments at all specific time points is often lacking or mixed.


What is Still Uncertain in the Research Landscape

Overall, the research describes a body of evidence where certainty remains low for certain types of outcomes or specific patient groups. Evidence quality varies across studies, with sample sizes that were modest or follow-up durations that were limited for many non-community-based uses. Findings were mixed or inconsistent in specific scenarios. The evidence highlights what is known, but it is important to understand that research provides context but not individual predictions, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Ivermet (FAQ)


Q: How long does Ivermet stay in your system?

A: According to official regulatory documents, the plasma half-life of the active ingredient, ivermectin, is approximately 18 hours following oral administration. The drug and its breakdown products are primarily eliminated from the body through the feces, with the total clearance process estimated to occur over about 12 days.


Q: Is it normal to feel tired after taking Ivermet?

A: Official information lists somnolence (drowsiness) and asthenia (lack of energy or strength) as common adverse reactions associated with the oral tablet. Feeling tired may be related to these commonly reported side effects. If fatigue is severe or persistent, consulting a healthcare professional is appropriate.


Q: Are there any serious side effects I should be aware of with Ivermet?

A: Yes, official labeling notes that some serious adverse reactions have been reported. These include the Mazzotti reaction, which is a severe inflammatory response associated with the rapid death of parasites in certain infections. In rare instances, serious neurological events such as seizures and encephalopathy have also been reported.


Q: Does Ivermet interact with common pain relievers like Tylenol or Advil?

A: Regulatory labeling provides specific warnings for strong CYP3A4 inhibitors and the anticoagulant warfarin, but there is no specific warning or contraindication listed in official documents regarding co-administration with over-the-counter pain relievers such as acetaminophen (Tylenol) or ibuprofen (Advil).


Q: What over-the-counter supplements should I avoid while taking Ivermet?

A: Official guidance often focuses on prescription drug interactions, but generally advises caution. It is important for patients to inform their healthcare provider about all medicines, including herbal products or vitamin supplements, as this allows for an assessment of potential unknown risks or interactions.


Q: Can I drink alcohol while I am taking Ivermet?

A: While alcohol is not always listed in the main interaction sections, patient-focused regulatory advice generally suggests consulting a doctor before consuming alcohol (ethanol) while taking ivermectin. This is because alcohol may potentially increase drug levels or contribute to common side effects like dizziness or nausea.


Q: What happens if I experience a skin rash after taking Ivermet?

A: A skin rash or pruritus (itching) is listed as a common side effect of Ivermet. However, signs of a serious allergic reaction, such as a severe rash, swelling (especially of the face, tongue, or throat), severe dizziness, or difficulty breathing, warrant immediate communication with a healthcare professional.


Q: Why does Ivermet need to be taken in a specific way?

A: Ivermet must be taken on an empty stomach as instructed in the official documents. This specific instruction is required because consuming the drug with a high-fat meal significantly increases the amount of drug the body absorbs, which can lead to unpredictable drug levels in the bloodstream. Taking it while fasting helps to maintain consistent and predictable systemic exposure.


Q: Is it okay to crush or split Ivermet tablets?

A: The official administration guidelines state that the tablets should generally be swallowed whole with water. However, the product information specifies that the tablets must be crushed before swallowing when administering the dose to children who are under six years of age (and who weigh at least 15 kg).


Q: What should I do if my side effects from Ivermet don't go away?

A: Official regulatory documents describe most common adverse reactions as being transient (short-lived). If any side effects, whether common or uncommon, are severe, troubling, or persist beyond a reasonable time frame, consulting a healthcare professional is recommended for guidance.


Q: What should I look for to know if Ivermet is working?

A: In clinical studies, the drug's effectiveness is measured by laboratory results showing a reduction in parasite counts or complete parasitological cure. At the patient level, an improvement in symptoms related to the underlying infection may be observed, alongside clinical measures of effectiveness.


Q: Is Ivermet the same as or similar to other anti-parasitic medicines?

A: Ivermet's active ingredient, ivermectin, belongs to the avermectin class of broad-spectrum antiparasitic agents. Its unique properties and mechanism of action set it apart from many other anti-parasitic medications.


Q: What is the difference between Ivermet and Stromectol?

A: Ivermet is the active drug ingredient, ivermectin. Stromectol is the registered brand name under which the oral tablet formulation of ivermectin is marketed and approved by regulatory bodies for specific human uses.


Q: What does the research say about the original, intended uses of Ivermet?

A: The drug's original regulatory approvals and current labeling indicate that it is intended for the treatment of certain parasitic infections, primarily intestinal strongyloidiasis and onchocerciasis (commonly known as river blindness).


Q: Is there a lot of scientific evidence supporting Ivermet's main uses?

A: Official regulatory approval is contingent on a body of scientific evidence. The drug's main uses are supported by evidence from clinical trials, including randomized controlled trials (RCTs), which evaluate outcomes such as parasite elimination and disease control.


Q: Can children take Ivermet?

A: According to official product information, the oral tablet formulation of Ivermet is not recommended for children who weigh less than 15 kilograms (approximately 33 pounds). Safety and effectiveness have not been established in patients below this minimum weight requirement.


Q: What if I forget to take my dose of Ivermet?

A: Ivermet is often a single-dose treatment. If a dose is missed, patients should refer to the instructions provided by their prescriber; generally, advice is given against doubling a dose to compensate for a missed one.


Q: Is there a generic version of Ivermet available?

A: Yes, the active ingredient, ivermectin, is widely available as a generic medication. Generic versions contain the same active ingredient, dose, and form as the brand name product.


Q: Does Ivermet interact with common vitamins like Vitamin D or C?

A: Official labeling only lists interactions with specific medications. However, regulatory bodies broadly advise patients to tell their doctor about all supplements, including common vitamins and herbs, to allow for an assessment of potential unknown risks or effects.


Q: Is it possible to be allergic to Ivermet?

A: Yes, it is possible. Regulatory guidelines state that the drug is contraindicated (must not be used) in patients who have a known hypersensitivity (severe allergic reaction) to ivermectin or any of the other ingredients in the formulation.


Q: How is Ivermet cleared from the body?

A: Ivermet is primarily metabolized (broken down) in the liver by an enzyme called CYP3A4. The drug and its byproducts are then excreted almost entirely through the feces over the course of several days.


Q: Does the time of day matter when taking Ivermet?

A: Regulatory documents state that the most important factor is the fasting condition, requiring the dose to be taken on an empty stomach (no food two hours before or two hours after). The specific time of day (morning, afternoon, or evening) is not regulated, provided this fasting requirement is met.


Q: Is Ivermet usually a one-time treatment or a course of treatment?

A: For initial infections like strongyloidiasis, the prescribed regimen is typically a single oral dose. For infections like onchocerciasis, it may be a single dose followed by potential re-treatment on a set schedule, often every 3 to 12 months, as determined by a healthcare provider.


Q: Why do some people experience temporary worsening of symptoms after taking Ivermet?

A: This temporary worsening is often linked to the Mazzotti reaction, which is listed in official documents as an adverse event. It is an immune response caused by the rapid death of large numbers of parasites in the body, which can lead to symptoms like fever, itching, swelling, and joint pain.


Q: Does Ivermet interact with grapefruit juice?

A: Ivermet is processed in the liver by the CYP3A4 enzyme. Because grapefruit juice is a known strong inhibitor of CYP3A4, it may increase the concentration of ivermectin in the blood. For this reason, consuming grapefruit juice while taking this medicine should generally be avoided.


Q: What are the typical instructions for taking Ivermet for river blindness?

A: Official administration instructions for river blindness (onchocerciasis) typically involve a single oral dose. Because the larval parasites are released in cycles, re-treatment is often required on a periodic basis, generally every 3 to 12 months, as determined by a healthcare provider.

How should Ivermet be stored and disposed of?

How to Store and Dispose of Ivermet Tablets

Official regulatory documents stipulate specific conditions for the storage and disposal of ivermectin tablets to maintain the drug's stability and quality.


Storage Requirements

Ivermectin tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and should not be exposed to excessive heat or moisture. To ensure stability, the tablets require protection from light and must be kept in the original, tightly closed container.

For safety, the product must be stored out of the sight and reach of children.


Disposal Instructions

Disposal of unused or expired ivermectin tablets must follow local regulatory requirements for pharmaceutical waste. The product should not be disposed of via household wastewater or thrown away in the regular trash. Patients are advised to consult their pharmacist or healthcare provider for instructions on proper collection and discard procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivermet found in:

A-Z Index: